BCL11A erythroid-specific enhancer

The BCL11A erythroid-specific enhancer is a non-coding regulatory DNA element located in intron 2 of the human BCL11A gene. It functions as a developmentally and lineage-specific enhancer, regulating BCL11A expression exclusively in erythroid (red blood cell) lineage cells. By controlling the transcription of BCL11A in erythroid cells, the enhancer is a key determinant of the fetal-to-adult hemoglobin switch, as BCL11A protein represses fetal (γ-globin) hemoglobin expression. Genetic variation in this enhancer correlates with natural differences in fetal hemoglobin levels, and disruption of this enhancer via genome editing in hematopoietic stem cells has emerged as a highly promising therapeutic strategy to induce fetal hemoglobin and treat disorders such as sickle cell disease and β-thalassemia. Editing the enhancer enables selective reduction of BCL11A in erythroid cells, sparing its critical functions in other tissues. This approach preserves hematopoietic stem cell self-renewal and function, addressing safety concerns associated with complete BCL11A knockout.

Other names

BCL11A intron 2 erythroid enhancerBCL11A enhancerBCL11A erythroid enhancer

Disruption or editing of the BCL11A erythroid-specific enhancer in hematopoietic stem/progenitor cells decreases BCL11A expression selectively in erythroid cells, derepressing γ-globin (fetal hemoglobin) expression. This compensates for defective or absent adult β-globin and ameliorates β-hemoglobinopathies